Supplemental materials

Supplemental Table 1. Relative risks of siblings and mothers for a specific type of early-onset cancer (diagnosed 0 to 26 years of age) given a proband with cancer, 1989 to 2015, California, USA.

, , ,	,,	No. of affected	
Cancer of the proband [†]	Cancer of the relative §	relatives §	SIR (95% CI)
	Leukemias	11	2.48 (0.98, 6.31)
	Lymphomas		· · · ·
	CNS tumors	6	
	VII. Hepatic tumors	1	
	Sarcomas	8	7.36* (1.12, 48.23)
	GCT	6	3.51 (0.78, 15.72)
Leukemias	Epithelial neoplasms	emias11 $2.48 (0.98, 6.31)$ homas6 $2.46 (0.7, 8.61)$ tumors6 $2.02 (0.65, 6.3)$ epatic tumors1 $0.41 (0.12, 1.43)$ omas8 $7.36^* (1.12, 48.23)$ 6 $3.51 (0.78, 15.72)$ elial neoplasms13 $5.37^* (1.52, 18.92)$ emias7 $7.47 (0.99, 56.59)$ homas4 $5.9 (0.55, 63.77)$ tumors2 $2.89 (0.27, 30.59)$ oblastoma1 $15.38 (0.01, 33561.02)$ oblastoma1 $12.99 (0.01, 15173.41)$ omas2 $7.07 (0.18, 281.41)$ 1 $1.93 (0.13, 29.54)$ elial neoplasms2 $2.67 (0.28, 25.71)$ emias5 $1.94 (0.57, 6.58)$	
	Leukemias	7	
	Lymphomas	4	5.9 (0.55, 63.77)
	CNS tumors	2	2.89 (0.27, 30.59)
	Neuroblastoma	1	15.38 (0.01, 33561.02)
	Retinoblastoma	1	40 (0, 9674536.43)
	Renal tumors	1	12.99 (0.01, 15173.41)
	Sarcomas	2	7.07 (0.18, 281.41)
	GCT	1	1.93 (0.13, 29.54)
Lymphomas	Epithelial neoplasms	2	2.67 (0.28, 25.71)
	Leukemias	5	1.94 (0.57, 6.58)
	Lymphomas	2	1.31 (0.27, 6.36)
	CNS tumors	11	6.19* (1.42, 26.93)
	Renal tumors	1	4.29 (0.07, 248.94)
	Sarcomas	6	8.97 (0.82, 98.5)
	GCT	2	1.81 (0.28, 11.72)
CNS tumors	Epithelial neoplasms	10	6.37* (1.33, 30.41)

	Other	1	0.65 (0.13, 3.18)
	Lymphomas	1	2.23 (0.12, 41.5)
	Neuroblastoma	1	10.31 (0.02, 5575.99)
	Sarcomas	1	4.78 (0.07, 348.18)
	GCT	1	3.33 (0.09, 119.39)
	Epithelial neoplasms	2	5.09 (0.22, 116)
Neuroblastoma	Other	1	2.23 (0.12, 41.5)
	Lymphomas	1	4.5 (0.07, 288.57)
	Retinoblastoma	10	454.55 (0, 249162343.25)
	VIII. Malignant bone tumors	1	4.5 (0.07, 288.57)
	Sarcomas	1	9.52 (0.02, 4033.89)
Retinoblastoma	Epithelial neoplasms	1	5.24 (0.06, 464.17)
	Lymphomas	1	3.02 (0.1, 91.14)
	CNS tumors	1	2.37 (0.12, 48.42)
	Renal tumors	1	15.87 (0.01, 39083.18)
	Sarcomas	2	13.33 (0.08, 2102.67)
	GCT	1	4.42 (0.07, 273.17)
Renal tumors	Epithelial neoplasms	3	9.17 (0.3, 282.58)
	Leukemias	1	4.08 (0.08, 214.07)
VII. Hepatic tumors	Epithelial neoplasms	1	9.52 (0.02, 4033.89)
	Leukemias	1	14.49 (0.01, 25216.18)
VIII. Malignant bone tumors	Epithelial neoplasms	1	16.39 (0.01, 45829.78)
	Leukemias	8	7.01* (1.12, 43.92)
	Lymphomas	1	1.37 (0.14, 13.5)
	CNS tumors	7	8.62 (0.98, 75.89)
	Neuroblastoma	1	11.11 (0.02, 7640.96)
	Renal tumors	2	19.8 (0.04, 9443.54)
	Sarcomas	10	31.45 (0.97, 1016.37)
Sarcomas	GCT	4	7.41 (0.51, 106.67)

	Epithelial neoplasms	6	7.56 (0.84, 68.17)
	Other	1	1.37 (0.14, 13.5)
	Leukemias	4	5.81 (0.55, 61.76)
	Lymphomas	2	4.06 (0.25, 66.15)
	CNS tumors	3	5.93 (0.38, 93.24)
	Neuroblastoma	1	19.23 (0, 103951.54)
	Renal tumors	1	16.67 (0.01, 49765.5)
	Sarcomas	2	9.66 (0.13, 717.76)
	GCT	3	7.71 (0.33, 178.63)
GCT	Epithelial neoplasms	4	6.92 (0.53, 91.15)
	Leukemias	4	8.39 (0.49, 143.23)
	Lymphomas	1	2.19 (0.12, 39.96)
	CNS tumors	3	7.56 (0.34, 169.55)
	Neuroblastoma	1	41.67 (0, 13012839.04)
	Sarcomas	2	10.99 (0.11, 1087.03)
	GCT	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	2.63 (0.11, 63.25)
Epithelial neoplasms	Epithelial neoplasms	24	40.68* (3.17, 521.85)
	Lymphomas	1	16.39 (0.01, 45829.78)
	CNS tumors	1	14.29 (0.01, 23561.37)
	Neuroblastoma	1	125 (0, 410967476948.84)
Other	Sarcomas	1	37.04 (0, 5610209.13)

[†] Cancers were classified into subgroups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (<u>https://seer.cancer.gov/iccc/iccc3.html</u>). [§] Affected relatives include mother and siblings of the proband diagnosed with early-onset cancer under 26 years of age. SIR, Standardized incidence ratio. CI, confidence interval.

Non-Latino White				Latino all races					Non-Latino API			Non-Latino Black			
Cancer of the proband [†]	No. of Probands	No. of affected relatives	SIR (95% CI)	No. of Probands	No. of affected relatives [§]	SIR (95% CI)		No. of Probands		s SIR (95% CI)	p- value ‡		No. of affected relatives §	SIR (95% CI)	p-value ‡
Overall	8119	50	2.60* (1.66, 4.06)	12736	78	3.36* (2.24, 5.05)	0.001	1677	11	4.58* (1.29 16.23)	, <0.00 1	1102	13	6.96* (1.66, 29.23) 6.58	<0.001
Leukemias	1646	11	2.11 (0.89, 4.96)	4374	21	2.35* (1.22, 4.53)	0.004	457	6	6.94 (0.84, 57.2) 20.29	<0.00 1	205	3	(0.36, 119.79) 5.14	<0.001
Lymphomas	1060	8	4.32* (1.02, 18.25)	1121	8	4.10* (1.01, 16.64)	0.88	226	4	(0.25, 1676.1)	0.001	187	1	(0.06, 437.14) 7.56	<0.001
CNS tumors	1728	12	2.63* (1.05, 6.58) 0.70	2242	12	2.86* (1.10, 7.43) 1.70	0.767	311	3	7.14 (0.35, 146.65) 6.55 (0.04,	1	239	3	(0.34, 169.66)	<0.001
Neuroblastoma	367	1	(0.14, 3.64)	490	2	(0.28, 10.32)	0.455	51	1	986.09)		48	0	NA 11.43	0.187
Retinoblastoma	126	2	3.65 (0.26, 51.45)	327	9	12.32* (1.24, 121.98)	0.016	35	0	NA	NA	30	1	(0.02, 8628.8) 8.82	0.127
Renal tumors	209	2	2.64 (0.28, 25.14)	442	3	2.91 (0.42, 20.03)	0.463	28	0	NA	NA	53	1	(0.02 (0.03, 2978.21)	0.122
Hepatic tumors	74	0	NA	200	1	2.43 (0.11, 51.51) 6.06	0.311	13	0	NA	NA	6	0	NA	NA
Bone tumors	73	0	NA	121	1	(0.05, 755.63)	0.306	13	0	NA	NA	17	0	NA 10.68	NA
Sarcomas	816	7	3.77 (0.89, 15.87) 3.42	1259	20	9.06* (2.42, 33.86) 6.20*	0.003	160	1	4.47 (0.07 281.59) 4.86 (0.06	0.001	132	3	(0.26, 430.82)	0.003
GCT	672	4	(0.56, 20.99)	1270	10	(1.32, 29.04)	0.04	184	1	366.27)		70	0	NA 22.57	0.007
Epithelial neoplasms	1458	14	8.60* (1.85, 39.96)	1046	15	15.16 * (2.11, 108.71) 5.86	0.032	239	2	13.25 (0.09, 2058.89)	<0.00 1	122	2	(0.03, 16333.1 6)	<0.001
Other	79	2	10.49	90	1	(0.05, 673.74)	0.313								

Supplementary Table 2. Relative risks of any early-onset cancer (diagnosed 0 to 26 years of age) among siblings and mothers by ethnic group, 1989 to 2015, California, USA.

			(0.12, 932.36)					8	0	NA	NA	19	0	NA	0.065
Hematologic			2.69*			2.48*				7.56* (1.12	, <0.00			6.15 (0.54,	
cancers¶	2702	19	(1.29, 5.62)	5484	27	(1.37, 4.50)	0.016	679	8	50.83)	1	391	4	69.81) 7.35 *	<0.001
			3.02*			4.98*				5.07 (0.96,	, <0.00			(1.25,	
Solid cancers [¶]	5471	37	(1.72, 5.28)	7323	62	(2.86, 8.68)	0.001	1021	7	26.88)	1	719	9	43.2)	<0.001

[†] Cancers were classified into subgroups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (<u>https://seer.cancer.gov/iccc/iccc3.html</u>).

[§] Affected relatives include mother and siblings of the proband diagnosed with early-onset cancer under 26 years of age.

[‡] p-value comparing the SIRs between non-Latino White and Latino all races using an approximate Chi-squared test.

¹ Hematologic cancers include group 1, leukemias, myeloproliferative diseases, and myelodysplastic diseases; group 2, lymphomas and reticuloendothelial neoplasms. Solid cancers include I group 3, CNS and miscellaneous intracranial and intraspinal neoplasms; group 4, neuroblastoma and other peripheral nervous cell tumors; group 5, retinoblastoma; group 6, renal tumors; group 7, hepatic tumors; group 8, malignant bone tumors; group 9, soft tissue and other extraosseous sarcomas; group 10, germ cell tumors, trophoblastic tumors, and neoplasms of gonads; group 11, other malignant epithelial neoplasms and malignant melanomas; group 12, other and unspecified malignant neoplasms. SIR, Standardized incidence ratio. CI, confidence interval.

		Over	rall		Non-Latino	White		_		
	Proband			No. of	No. of		No. of Proband	No. of affected		
Cancer of the proband	S	s §	SIR (95% CI)	Probands	relatives §	SIR (95% CI)	S	relatives §	SIR (95% CI)	p-value [‡]
Leukemias	8500	11	2.48 (0.98, 6.31) 5.90	1646	2	2.19 (0.28, 17.02) 9.03	4374	4	1.45 (0.45, 4.74)	0.083
Lymphomas	2928	4	(0.55, 63.82) 6.19 *	1060	3	(0.3, 270.64) 5.07	1121	0	NA 4.66	NA
CNS tumors	5739	11	(1.42, 26.93) 10.28	1728	4	(0.56, 46.02)	2242	3	(0.41, 53.56)	0.483
Neuroblastoma	1445	1	(0.02, 5501.95)	367	0	NA 194.8	490	0	NA	NA
Retinoblastoma	718	10	446.17 (0, 216413526.63) 15.95	126	1	(0, 1479721536316 56)	327	7	662.31 (0, 126150580638.22)	0.009
Renal tumors	1069	1	(0.01, 39978.15)	209	0	NA	442	1	39.09 (0, 8211440.71)	NA
VII. Hepatic tumors VIII. Malignant bone	414	0	NA	74	0	NA	200	0	NA	NA
tumors	249	0	NA 31.49	73	0	NA 18.88	121	0	NA 35.96	NA
Sarcomas	2915	10	(0.97, 1020.26) 7.71	816	2	(0.05, 7792.14)	1259	5	(0.19, 6895.34) 8.63	0.155
GCT	2423	3	(0.33, 178.48) 40.68 *	672	0	NA 21.31	1270	2	(0.15, 506.54) 55.65	NA
Epithelial neoplasms	3050	24	(3.17, 521.78)	1458	9	(1.04, 434.91)	1046	9	(0.43, 7278.24)	<0.001
Other	255	0	NA	79	0	NA	90	0	NA	NA
Hematologic cancers [¶]	11404	22	2.68* (1.35, 5.32) 6.78*	2702	6	2.64 (0.72, 9.71) 4.41 *	5484	7	1.56 (0.62, 3.94) 7.94 *	0.133
Solid cancers [¶]	17849	112	(4.18, 10.98)	5471	31	(2.10, 9.23)	7323	50	(3.64, 17.34)	0.005

Supplementary Table 3. Relative risks of the same type of early-onset cancer with the proband among siblings and mothers by ethnic group, 1989 to 2015, California, USA.

[†] Cancers were classified into subgroups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (<u>https://seer.cancer.gov/iccc/iccc3.html</u>).

[§] Affected relatives include mother and siblings of the proband diagnosed with early-onset cancer under 26 years of age.

[‡] p-value comparing the SIRs between non-Latino White and Latino all races using an approximate Chi-squared test.

[¶] Hematologic cancers include group 1, leukemias, myeloproliferative diseases, and myelodysplastic diseases; group 2, lymphomas and reticuloendothelial neoplasms. Solid cancers include I group 3, CNS and miscellaneous intracranial and intraspinal neoplasms; group 4, neuroblastoma and other peripheral nervous cell tumors; group 5, retinoblastoma; group 6, renal tumors; group 7, hepatic tumors; group 8, malignant bone tumors; group 9, soft tissue and other extraosseous sarcomas; group 10, germ cell tumors, trophoblastic tumors, and neoplasms of gonads; group 11, other malignant epithelial neoplasms and malignant melanomas; group 12, other and unspecified malignant neoplasms. SIR, Standardized incidence ratio. CI, confidence interval.

All cancers The same type of cancer No. of No. of No. of affected SIR affected SIR Cancer of the proband [†] probands relatives § (95% CI) relatives § (95% CI) 2.70* 1.86 5 Lymphoid leukemias 6705 25 (1.60, 4.55)(0.04, 77.51)4.61* 26.35 (0.21, 3254.81) Acute myeloid leukemias 1317 9 (1.44, 14.83)3 7.12* 10.30 1399 9 2 Hodgkin lymphomas (1.67, 30.35)(0.03, 3755.90)Non-Hodgkin lymphomas 4.02 11.35 (except Burkitt lymphoma) 5 985 (0.81, 20.01)1 (0.00, 47646.79)**Ependymomas and choroid** 2.46 0 plexus tumor 561 2 (0.42, 14.51)NA 7.62 3.60* Astrocytomas 1965 11 (1.33, 9.71)2 (0.02, 2780.03)Intracranial and intraspinal 2.67 11.70 embryonal tumors 1010 6 (0.80, 8.96)1 (0.00, 49115.47)5.34* 58.00 Other gliomas 815 8 (1.08, 26.52) 2 (0.16, 21151.56)Other specified intracranial and 5.48* 22.91 intraspinal neoplasms 1470 5 (1.19, 25.27) 2 (0.06, 8355.61)Neuroblastoma and 2.06 8.95 ganglioneuroblastoma 6 1 1409 (0.71, 5.97)(0.00, 37570.97)Nephroblastoma and other 3.67* 16.42 nonepithelial renal tumors 1032 6 (1.05, 12.83)1 (0.00, 68950.65)8.46* 0 Rhabdomyosarcomas 719 11 NA (1.84, 38.84) Fibrosarcomas to peripheral nerve sheath tumors to and 10.46 390.23* 2 other fibrous neoplasms 434 7 (0.95, 114.82)(1.07, 142319.04)Other specified soft tissue 7.57* 58.45 1624 11 5 sarcomas (2.20, 26.07)(1.40, 2438.32)Malignant gonadal germ cell 5.44* 6.69 2 tumors 1030 12 (1.67, 17.71)(0.02, 2439.81)3.65 22.34 Malignant melanomas 788 2 (0.42, 31.77)1 (0.01, 93804.63)

Supplemental Table 4. Relative risks of any early-onset cancer (diagnosed at 0 to 26 years of age) for siblings and mothers of the same type of cancer with the proband given a proband with cancer by subgroups, 1989 to 2015, California, USA.

Other and unspecified			18.12*		115.36*
carcinomas	1845	20	(3.85, 85.29)	17	(15.25, 872.55)

[†]Cancers were classified into subgroups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (<u>https://seer.cancer.gov/iccc/iccc3.html</u>). [§] Affected relatives include mother and siblings of the proband diagnosed with early-onset cancer under 26 years of age. SIR, Standardized incidence ratio. CI, confidence interval. * Statistically significant standardized incidence ratio with p<0.05 assuming a Poisson distribution.

		Overal	I	Ν	on-Latino \	White		Latino all r	aces	_
		No. of			No. of			No. of		_
Cancer of the	No. of	affected		No. of	affected		No. of	affected		+
proband [†]	Probands	relatives s		Probands	relatives [§]	SIR (95% CI)	Probands	relatives [§]	SIR (95% CI)	p-value [‡]
• "	00070		1.56*		4.0	0.93	40700	0.5	1.51*	
Overall	29072	72	(1.17, 2.08) 1.40	8119	18	(0.60, 1.46) 0.38	12736	35	(1.00, 2.26) 1.23	0.003
Leukemias	8500	22	(0.85, 2.29)	1646	2	(0.16, 0.90)	4374	11	(0.64, 2.37)	0.003
	0000		2.88*	1010	-	2.15	101 1		2.04	
Lymphomas	2928	11	(1.06, 7.86)	1060	4	(0.51, 9.08)	1121	4	(0.50, 8.28)	0.916
			2.42*			1.53			1.19	
CNS tumors	5739	23	(1.28, 4.57)	1728	7	(0.61, 3.83)	2242	5	(0.46, 3.09)	0.359
			1.57						0.85	
Neuroblastoma	1445	5	(0.52, 4.70)	367	0	NA	490	1	(0.14, 5.16)	0.313
	- 10		6.79*	400		1.81	-		10.95*	
Retinoblastoma	718	11	(1.46, 31.64)	126	1	(0.13, 25.25)	327	8	(1.11, 108.43)	0.011
Denal from and	1000	4	1.81	200	0	NIA	440	3	2.91	0.077
Renal tumors	1069	4	(0.48, 6.77) 1.20	209	0	NA	442	3	(0.42, 20.03)	0.077
VII. Hepatic tumors	414	1	(0.14, 10.2)	74	0	NA	200	0	NA	NA
	717		3.28	14	0		200	0	147 (
VIII. Malignant bone			(0.09,						6.06	
tumors	249	1	114.19)	73	0	NA	121	1	(0.05, 755.63)	0.306
			5.25*			2.15			4.96*	
Sarcomas	2915	23	(2.06, 13.41)	816	4	(0.51, 9.04)	1259	11	(1.33, 18.52)	0.031
			4.70			2.57			4.33	
GCT	2423	13	(1.45, 15.29)	672	3	(0.42, 15.72)	1270	7	(0.93, 20.25)	0.098
			5.83*			3.67		_	5.03	
Epithelial neoplasms	3050	13	(1.57, 21.67)	1458	6	(0.79, 16.98)	1046	5	(0.70, 35.87)	0.165
			8.03			10.49			5.00	
Other	055	n	(0.33,	70	2	(0.12,	00	1	5.86	0.040
Other	255	3	198.63)	79	2	932.36)	90	I	(0.05, 673.74)	0.313
Hematologic cancers [¶]	11404	29	1.48 (0.95, 2.31)	2702	6	0.85 (0.41, 1.76)	5484	13	1.19 (0.66, 2.16)	0.023
nematorogic cancers"	11404	29	(0.95, 2.51) 2.64 *	2102	0	(0.41, 1.76) 1.46	0404	10	(0.00, 2.10) 2.57 *	0.023
Solid cancers [¶]	17849	71	(1.81, 3.86)	5471	18	(0.84, 2.56)	7323	32	(1.47, 4.47)	0.013
			(0.1.1	.0	(0.01, 2.00)		<u> </u>	 /	

Supplementary Table 5. Relative risks of all pediatric cancers (diagnosed 0 to 15 years of age) among siblings and mothers by ethnic group, 1989 to 2015, California, USA.

[†] Cancers were classified into subgroups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (<u>https://seer.cancer.gov/iccc/iccc3.html</u>).

§ Affected relatives include mother and siblings of the proband diagnosed with early-onset cancer under 26 years of age.

[‡] p-value comparing the SIRs between non-Latino White and Latino all races using an approximate Chi-squared test.

¹ Hematologic cancers include group 1, leukemias, myeloproliferative diseases, and myelodysplastic diseases; group 2, lymphomas and reticuloendothelial neoplasms. Solid cancers include I group 3, CNS and miscellaneous intracranial and intraspinal neoplasms; group 4, neuroblastoma and other peripheral nervous cell tumors; group 5, retinoblastoma; group 6, renal tumors; group 7, hepatic tumors; group 8, malignant bone tumors; group 9, soft tissue and other extraosseous sarcomas; group 10, germ cell tumors, trophoblastic tumors, and neoplasms of gonads; group 11, other malignant epithelial neoplasms and malignant melanomas; group 12, other and unspecified malignant neoplasms. SIR, Standardized incidence ratio. CI, confidence interval.

		Ove	erall		Non-Lati	no White				
Cancer of the proband [†]	No. of FPMs	No. of SPMs	SIR (95% CI)	No. of FPMs	No. of SPMs	SIR (95% CI)	No. of FPMs	Latino (a No. of SPMs	SIR (95% CI)	p- value [‡]
-			9.27*			12.05			5.82	
Leukemias	8,543	41	(3.65 to 23.56) 13.27*	1,649	11	(1.55 to 93.71) 12.05	4,385	16	(1.78 to 18.96) 11.29	0.001
Lymphomas	2,960	9	(1.23 to 143.48) 16.39*	1,063	4	(0.40 to 361.60) 15.19	1,124	3	(0.25 to 505.82) 17.08	
CNS tumors	5,877	29	(3.76 to 71.56) 20.62 (0.04 to	1,765	12	(1.67 to 137.80) 51.28 (0.00 to	2,277	11	(1.49 to 196.43)	0.431
Neuroblastoma	1,450	2	11151.98)	369	2	1047532.66)	491	0	NA	
Retinoblastoma	728	0		127	0	NA	334	0	NA	
Renal tumors VII. Hepatic	1,078	0		209	0	NA	444	0	NA	
tumors VIII. Malignant	417	0		74	0	NA	200	0	NA	
bone tumors	250	0		73	0	NA 47.17	121	0	NA 50.36	
			50.31*			(0.11 to			(0.26 to	
Sarcomas	3,028	16	(1.56 to 1626.19) 5.14	850	5	19415.87)	1,297	7	9665.53) 8.62	0.353
GCT Epithelial	2,468	2	(0.22 to 119.09) 16.95 *	679	0	NA 14.18	1,287	2	(0.15 to 504.41) 24.69	
neoplasms	3,479	10	(1.32 to 217.44)	1,489	6	(0.70 to 288.80)	1,057	4	(0.19 to 3216.7)	0.005
Other	261	0		79	0	NA	90	0	NA	
Hematologic			6.10*			6.61*			4.23*	
cancers [¶]	11,553	50	(3.08, 12.10) 1.82*	2,727	15	(1.80, 24.29) 1.85	5,528	19	(1.68, 10.68) 2.06	0.012
Solid cancers [¶]	18,893	30	(1.12, 2.94)	5,673	13	(0.88, 3.87)	7,551	13	(0.95, 4.51)	0.681

Supplemental Table 6. Relative risks of second primary malignancies of the same type of early-onset cancer (diagnosed 0 to 26 years of age) with the first primary malignancy by ethnic groups, California, USA.

SIR, Standardized incidence ratio. CI, confidence interval. FPM, first primary malignancy. SPM, second primary malignancy.

[†] Cancers were classified into subgroups as defined by the International Classification of Childhood Cancer, Third edition (ICCC-3, November 2012) (<u>https://seer.cancer.gov/iccc/iccc3.html</u>).

[‡] p-value comparing the SIRs between non-Latino White and Latino all races using an approximate Chi-squared test.

[¶] Hematologic cancers include group 1, leukemias, myeloproliferative diseases, and myelodysplastic diseases; group 2, lymphomas and reticuloendothelial neoplasms. Solid cancers include I group 3, CNS and miscellaneous intracranial and intraspinal neoplasms; group 4, neuroblastoma and other peripheral nervous cell tumors; group 5, retinoblastoma; group 6, renal tumors; group 7, hepatic tumors; group 8, malignant bone tumors; group 9, soft tissue and other extraosseous sarcomas; group 10, germ cell tumors, trophoblastic tumors, and neoplasms of gonads; group 11, other malignant epithelial neoplasms and malignant melanomas; group 12, other and unspecified malignant neoplasms. SIR, Standardized incidence ratio. CI, confidence interval. FPM, first primary malignancy. SPM, second primary malignancy. * Statistically significant standardized incidence ratio with p<0.05 assuming a Poisson distribution.

Supplemental Figure legends

Supplemental Figure 1. Relative risks of all cancers for mothers given a proband with cancer.

A. Relative risks of all cancers for mothers given a proband with cancer by 5-year age group.

B. Age-adjusted incidence rate of all cancers by ethnic group in SEER 13.


AAIR in SEER 13, age-adjusted incidence rate of all cancers among females derived from the Surveillance, Epidemiology, and End Results (SEER) Program version 13 among female patients diagnosed in California between 1992 to 2015.

The axis for SIR was natural log-transformed. The error bars represent natural log-transformed upper and lower confidence limits of the SIR. Age (years) represent the age of first primary cancer diagnosis for a mother.

The SIR was 5.89 (95% CI: 4.25 to 8.16) for all mother cases age 15-39; 17.56 (95% CI: 6.24 to 49.42) for non-Latino White mother cases age 15-39; 5.19 (95% CI: 3.24 to 8.31) for Latino mother cases age 15-39.

* P-value < 0.001 comparing the SIR of age 15-39 for non-Latino White to Latino subjects using an approximate Chi-square test.

Abbreviations: SIR, Standardized incidence ratio. AAIR: age-adjusted incidence rate. SEER 13, Surveillance, Epidemiology, and End Results Program version 13.



Supplementary Figure 1B.

